In line with our ex vivo findings, patients with higher WNT5A/SFRP5 myocardial expression had a significantly higher risk for the same composite outcome of cardiac mortality, nonfatal MI, and nonfatal cardioembolic stroke (HR: 3.941; 95% CI: 1.607-9.661; P = 0.003 for highest tertile of WNT5A/SFRP5 myocardial expression vs the rest) (Figure 7B). Here, SFRP5 is linked to cardioembolic stroke.